REZN

Hash CNSX:REZN Stock Report

Last Price

CA$0.005

Market Cap

CA$1.4m

7D

0%

1Y

-75.0%

Updated

05 Oct, 2022

Data

Company Financials
REZN fundamental analysis
Snowflake Score
Valuation2/6
Future Growth0/6
Past Performance0/6
Financial Health4/6
Dividends0/6

REZN Stock Overview

The Hash Corporation focuses on the production and sale of cannabis-based hashish and other cannabis products in Canada.

Hash Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Hash
Historical stock prices
Current Share PriceCA$0.005
52 Week HighCA$0.025
52 Week LowCA$0.005
Beta0
1 Month Change0%
3 Month Change0%
1 Year Change-75.00%
3 Year Changen/a
5 Year Changen/a
Change since IPO-92.86%

Recent News & Updates

Shareholder Returns

REZNCA PharmaceuticalsCA Market
7D0%-3.2%3.2%
1Y-75.0%-65.3%-3.0%

Return vs Industry: REZN underperformed the Canadian Pharmaceuticals industry which returned -64.8% over the past year.

Return vs Market: REZN underperformed the Canadian Market which returned -2.5% over the past year.

Price Volatility

Is REZN's price volatile compared to industry and market?
REZN volatility
REZN Average Weekly Movementn/a
Pharmaceuticals Industry Average Movement12.7%
Market Average Movement10.1%
10% most volatile stocks in CA Market18.3%
10% least volatile stocks in CA Market3.8%

Stable Share Price: Insufficient data to determine REZN's volatility over the past 3 months.

Volatility Over Time: Insufficient data to determine REZN's volatility change over the past year.

About the Company

FoundedEmployeesCEOWebsite
1967n/aChris Savoiehttps://www.thehashcorporation.com

The Hash Corporation focuses on the production and sale of cannabis-based hashish and other cannabis products in Canada. The company was formerly known as Senternet Phi Gamma Inc. and changed its name to The Hash Corporation in July 2019. The Hash Corporation was incorporated in 1967 and is headquartered in Toronto, Canada.

Hash Fundamentals Summary

How do Hash's earnings and revenue compare to its market cap?
REZN fundamental statistics
Market CapCA$1.40m
Earnings (TTM)-CA$2.28m
Revenue (TTM)CA$1.37m

1.0x

P/S Ratio

-0.6x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report
REZN income statement (TTM)
RevenueCA$1.37m
Cost of RevenueCA$787.94k
Gross ProfitCA$586.77k
Other ExpensesCA$2.86m
Earnings-CA$2.28m

Last Reported Earnings

Jun 30, 2022

Next Earnings Date

n/a

Earnings per share (EPS)-0.0081
Gross Margin42.68%
Net Profit Margin-165.57%
Debt/Equity Ratio23.5%

How did REZN perform over the long term?

See historical performance and comparison
We’ve recently updated our valuation analysis.

Valuation

Is REZN undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

2/6

Valuation Score 2/6

  • Price-To-Sales vs Peers

  • Price-To-Sales vs Industry

  • Price-To-Sales vs Fair Ratio

  • Below Fair Value

  • Significantly Below Fair Value

  • Analyst Forecast

Key Valuation Metric

Which metric is best to use when looking at relative valuation for REZN?

Other financial metrics that can be useful for relative valuation.

REZN key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenue1.1x
Enterprise Value/EBITDA-0.7x
PEG Ration/a

Price to Sales Ratio vs Peers

How does REZN's PS Ratio compare to its peers?

REZN PS Ratio vs Peers
The above table shows the PS ratio for REZN vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyPSEstimated GrowthMarket Cap
Peer Average5.9x
SE Sweet Earth Holdings
3.2xn/aCA$896.9k
PULL Pure Extracts Technologies
2.5xn/aCA$2.3m
VIN Vinergy Capital
14.5xn/aCA$2.6m
WIB West Island Brands
0.5xn/aCA$2.1m
REZN Hash
1xn/aCA$1.4m

Price-To-Sales vs Peers: REZN is good value based on its Price-To-Sales Ratio (1x) compared to the peer average (5.9x).


Price to Earnings Ratio vs Industry

How does REZN's PE Ratio compare vs other companies in the CA Pharmaceuticals Industry?

Price-To-Sales vs Industry: REZN is good value based on its Price-To-Sales Ratio (1x) compared to the Canadian Pharmaceuticals industry average (1.3x)


Price to Sales Ratio vs Fair Ratio

What is REZN's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

REZN PS Ratio vs Fair Ratio.
Fair Ratio
Current PS Ratio1x
Fair PS Ration/a

Price-To-Sales vs Fair Ratio: Insufficient data to calculate REZN's Price-To-Sales Fair Ratio for valuation analysis.


Share Price vs Fair Value

What is the Fair Price of REZN when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: Insufficient data to calculate REZN's fair value for valuation analysis.

Significantly Below Fair Value: Insufficient data to calculate REZN's fair value for valuation analysis.


Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

Analyst Forecast: Insufficient data to show price forecast.


Discover undervalued companies

Future Growth

How is Hash forecast to perform in the next 1 to 3 years based on estimates from 0 analysts?

Future Growth Score

0/6

Future Growth Score 0/6

  • Earnings vs Savings Rate

  • Earnings vs Market

  • High Growth Earnings

  • Revenue vs Market

  • High Growth Revenue

  • Future ROE


70.8%

Forecasted Pharmaceuticals & Biotech industry annual growth in earnings

In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Hash has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.


Discover growth companies

  • Examine Hash's financial health to determine how well-positioned it is against times of financial stress by looking at its level of debt over time and how much cash it has left.
  • Hash competitive advantages and company strategy can generally be found in its financial reports archived here.

Past Performance

How has Hash performed over the past 5 years?

Past Performance Score

0/6

Past Performance Score 0/6

  • Quality Earnings

  • Growing Profit Margin

  • Earnings Trend

  • Accelerating Growth

  • Earnings vs Industry

  • High ROE


-57.1%

Historical annual earnings growth

Earnings and Revenue History

Quality Earnings: REZN is currently unprofitable.

Growing Profit Margin: REZN is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: REZN is unprofitable, and losses have increased over the past 5 years at a rate of 57.1% per year.

Accelerating Growth: Unable to compare REZN's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: REZN is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (39.8%).


Return on Equity

High ROE: REZN has a negative Return on Equity (-493%), as it is currently unprofitable.


Discover strong past performing companies

Financial Health

How is Hash's financial position?

Financial Health Score

4/6

Financial Health Score 4/6

  • Short Term Liabilities

  • Long Term Liabilities

  • Debt Level

  • Reducing Debt

  • Stable Cash Runway

  • Forecast Cash Runway

Financial Position Analysis

Short Term Liabilities: REZN's short term assets (CA$639.4K) exceed its short term liabilities (CA$342.3K).

Long Term Liabilities: REZN has no long term liabilities.


Debt to Equity History and Analysis

Debt Level: REZN's net debt to equity ratio (18%) is considered satisfactory.

Reducing Debt: REZN had negative shareholder equity 5 years ago, but is now positive and has therefore improved.


Balance Sheet


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: REZN has less than a year of cash runway based on its current free cash flow.

Forecast Cash Runway: REZN has less than a year of cash runway if free cash flow continues to reduce at historical rates of 63% each year


Discover healthy companies

Dividend

What is Hash current dividend yield, its reliability and sustainability?

Dividend Score

0/6

Dividend Score 0/6

  • Notable Dividend

  • High Dividend

  • Stable Dividend

  • Growing Dividend

  • Earnings Coverage

  • Cash Flow Coverage

Dividend Yield vs Market

Hash Dividend Yield vs Market
How does Hash dividend yield compare to the market?
SegmentDividend Yield
Company (Hash)n/a
Market Bottom 25% (CA)1.9%
Market Top 25% (CA)5.9%
Industry Average (Pharmaceuticals)2.6%
Analyst forecast in 3 Years (Hash)n/a

Notable Dividend: Unable to evaluate REZN's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate REZN's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if REZN's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if REZN's dividend payments have been increasing.


Earnings Payout to Shareholders

Earnings Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Cash Payout to Shareholders

Cash Flow Coverage: Unable to calculate sustainability of dividends as REZN has not reported any payouts.


Discover strong dividend paying companies

Management

How experienced are the management team and are they aligned to shareholders interests?

3.3yrs

Average management tenure


CEO

Chris Savoie

3.25yrs

Tenure

Chris Savoie has been Chief Executive Officer and Director of The Hash Corporation (formerly, Senternet Phi Gamma Inc.) since July 8, 2019.


Leadership Team

Experienced Management: REZN's management team is considered experienced (3.3 years average tenure).


Board Members

Experienced Board: REZN's board of directors are considered experienced (3.8 years average tenure).


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Ownership Breakdown

What is the ownership structure of REZN?
Owner TypeNumber of SharesOwnership Percentage

Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.

Company Information

The Hash Corporation's employee growth, exchange listings and data sources


Key Information

  • Name: The Hash Corporation
  • Ticker: REZN
  • Exchange: CNSX
  • Founded: 1967
  • Industry: Pharmaceuticals
  • Sector: Pharmaceuticals & Biotech
  • Implied Market Cap: CA$1.401m
  • Shares outstanding: 280.12m
  • Website: https://www.thehashcorporation.com

Location

  • The Hash Corporation
  • 1 Adelaide Street East
  • Suite 801
  • Toronto
  • Ontario
  • M5C 2V9
  • Canada


Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
REZNCNSX (Canadian National Stock Exchange)YesCommon SharesCACADJun 2021
REZN.FOTCPK (Pink Sheets LLC)YesCommon SharesUSUSDJun 2021

Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2022/10/05 00:00
End of Day Share Price2022/09/16 00:00
Earnings2022/06/30
Annual Earnings2021/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.